KRAS and melanoma: Furthermore, besides SF3B1 and KIT mutations, other variants have been described in the context of mucosal melanoma, including amplifications of CCND1, MDM2 and KRAS ([15, 24]), however this was not assessed this cohort and could represent a source of additional driver eventsin this cohort.